Corebridge Financial Inc. Sells 2,100 Shares of Omeros Co. (NASDAQ:OMER)

Corebridge Financial Inc. lessened its holdings in Omeros Co. (NASDAQ:OMER) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 27,808 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the quarter. Corebridge Financial Inc.’s holdings in Omeros were worth $275,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Truvestments Capital LLC lifted its position in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Omeros during the fourth quarter worth about $46,000. BNP Paribas Financial Markets boosted its stake in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares in the last quarter. Picton Mahoney Asset Management boosted its position in Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 4,404 shares during the period. Finally, MML Investors Services LLC lifted its position in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Tuesday, April 1st. Finally, StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Trading Up 14.8 %

Shares of OMER opened at $6.73 on Friday. Omeros Co. has a 1-year low of $2.97 and a 1-year high of $13.60. The firm has a market capitalization of $390.77 million, a price-to-earnings ratio of -2.91 and a beta of 2.35. The firm’s 50-day moving average price is $8.21 and its 200-day moving average price is $7.75.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same quarter in the previous year, the company earned ($0.15) EPS. On average, research analysts forecast that Omeros Co. will post -3.09 EPS for the current fiscal year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.